Abstract: An implantable emergency management drug delivery system configured to deliver a medicament to reverse the effects of a drug overdose. The implantable emergency management drug delivery system including an implantable infusion pump configured to infuse a first medicament, and an emergency handling device having at least one physiological sensor configured to monitor a condition of a patient for a possibility of an overdose from the first medicament, a communication module configured to communicate the possibility of an overdose to the implantable infusion pump, and an implantable medicament delivery mechanism configured to deliver a second medicament to reduce one or more adverse physiological effects of the first medicament.

Abstract: A medicament delivery device includes a generally elongated tubular housing having opposite proximal and distal parts; a needle shield sleeve slidably and coaxially arranged inside the housing with a proximal part of the sleeve protruding a distance outside the proximal part of the housing; a syringe carrier mechanism having a syringe carrier slidably and coaxially arranged within the needle shield sleeve, a syringe having a stopper, a medicament, and a needle, the syringe being coaxially arranged within the syringe carrier; and a holding member connected to the syringe carrier; a first activator member an a second activator member; a drive mechanism adapted to accumulate a drive force for moving the syringe carrier mechanism in a first step and a second step. The second activator member is arranged within an information device for producing audible, visual, and/or tactile feedback to a user about a completed injection.

Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: A bariatric device and method of causing at least partial satiety in a recipient includes positioning a body in a recipient, the body having a wall defining a lumen, the wall configured to generally conform to the shape and size of the proximal cardiac portion of the stomach. Force is exerted with the wall on the proximal cardiac portion of the stomach in the absence of food thereby activating receptors located in the proximal cardiac portion of the stomach, thereby influencing a neurohormonal feedback mechanism of the recipient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.

Abstract: A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

Abstract: Implementations illustrated herein discloses a method of controlling drug titration to a patient, the method including receiving, using a processor, a sequence of depth images, each depth image including depth information for at least a portion of the patient, determining, using the processor, a sequence of physiological signals for the patient based on the sequence of depth images, analyzing, using the processor, the sequence of physiological signals for the patient to determine a change in a condition of the patient, and generating a signal to a drug infusion pump in response to determining the change in the condition of the patient.

Abstract: Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device capable of delivering fluid to a patient involves predicting, by a control system associated with the infusion device, a future occurrence of an event based at least in part on historical data associated with the patient, and prior to the future occurrence of the event, automatically adjusting a control parameter for operating the infusion device based at least in part on the event and automatically operating an actuation arrangement of the infusion device to deliver the fluid to the patient based at least in part on a current measurement of the physiological condition and the adjusted control parameter.

Abstract: A medical pump includes a reader configured to read drug identification information, a storage unit that stores the drug identification information read by the reader, a notification unit, and a control unit, in which when the reader reads drug identification information anew while the drug identification information is stored in the storage unit, the control unit compares the drug identification information being stored in the storage unit with the drug identification information read anew by the reader, and when the drug identification information being stored in the storage unit does not match the drug identification information read anew by the reader, the control unit causes the notification unit to notify of non-matching between drugs.

Abstract: An intravenous delivery system may operate by gravity feed, and may have a liquid source containing a liquid, a drip unit that receives the liquid from the liquid source, and tubing that receives the liquid from the drip unit for delivery to a patient. A flow rate sensor may be used to measure a flow rate of liquid through the intravenous delivery system, and may generate a flow rate signal indicative of the flow rate. A controller may receive the signal, and may compare the flow rate with a desired flow rate. If the flow rate is more or less than the desired flow rate, the controller may transmit a control signal to a flow rate regulator. The flow rate regulator may receive the control signal and, in response, modify the flow rate to bring the flow rate closer to the desired flow rate.

Abstract: An iontophoresis system includes a preloaded reservoir containing one or more doses of a therapeutic agent. As a result, the therapeutic agent does not have to be loaded into the reservoir prior to use. In such a system, the preloaded reservoir is generally disposable. Various components of the iontophoresis system can be combined with the reservoir in a disposable cartridge that is selectively connectable to other, reusable components of the iontophoresis system. In addition, the entire iontophoresis system can be formed from one or more disposable, one-time-use modules.

Abstract: Glucose control systems are disclosed. An ambulatory medicament pump that is configured to wirelessly transmit one or more of a plurality of glucose control parameters and glucose control therapy data to a second ambulatory medicament pump is disclosed. A control system for transferring historical pump data from a first ambulatory medicament pump to a second ambulatory medicament pump is also disclosed. The control system can receive the historical pump data from a first ambulatory medicament pump, determine that at least one of a plurality of pairing conditions is satisfied to connect the data interface to the second ambulatory medicament pump, transmit, via the data interface, a pairing signal to the second ambulatory medicament pump, and transmit at least one of the therapy data associated with the delivery of the glucose control therapy or the glucose control parameter.

Abstract: The disclosure relates to a method which includes i) prompting input of: a creatinine clearance (CrCl) of a subject; whether the subject is being initiated or escalated on sotalol hydrochloride; an amount of an oral target dosage of sotalol hydrochloride for the subject; and optionally a projected start time for sotalol hydrochloride infusion; and ii) executing computer executable instructions to derive from a set of rules a sotalol hydrochloride dosing protocol for the subject based on the inputs. The disclosure also relates to systems and medical devices configured to perform one or more steps of the method, as well as a non-transitory computer-readable storage medium comprising computer-executable instructions or software stored thereon capable of performing one or more steps of the method.

Abstract: A fluid injection system including a graphical user interface, a fluid control module operatively connected to the graphical user interface, a monitoring control module provided in at least one of the graphical user interface and the fluid control module, a fluid injector operatively connected to the graphical user interface and the fluid control module, at least one fluid path set in fluid communication with the fluid control module, and a hemodynamic monitoring system operatively connected to the fluid path set and the monitoring control module. The hemodynamic monitoring system may be configured to receive electrical signals regarding pressure waves formed in medical fluid directed through the fluid path set based on a location of the fluid path set in a patient's vasculature, to convert the electrical signals to pressure wave form information, and to send the pressure wave form information to the monitoring control module.

Abstract: The invention relates to an infusion catheter device. This catheter device 10 has an elongate, substantially tubular shape defining a longitudinal axis, a distal end (D) and a proximal end (P), configured to be introduced into a conduit (50) having an inner wall (54) and an outer wall (56) and comprising at least one partial or total obstruction (60) or occlusion to be treated, said device comprising, at its distal end (D), one or more infusion orifices (16, 18, 20, 22) for an infusion liquid (LI), and, upstream from the one or more infusion orifices, at the proximal side (P) of the infusion catheter (10), at least one obturating element (70) for temporary obturating, configured to treat said obstruction (60) or occlusion and to perform the infusion of the infusion liquid (LI) downstream from the obturating element (70) and in the obturating position. This device is suitable in particular for cardiac surgery and interventional cardiology.

Abstract: The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

Abstract: Embodiments provide an oxygen supply device having multiple operational states including a first state and a second state. In the first state, the oxygen supply device is controllable to a local control instruction such that the oxygen supply device can be operated by a user physically located within a proximity of the oxygen supply device. In the second state, the oxygen supply device is only controllable to a remote-control instruction such that the oxygen supply device can be operated by a user remote to the oxygen supply device. For example, the user can be located in an office remote to a location of the oxygen supply device, which, for example, may be placed at a patient's home. In the second state, the user is enabled to control the oxygen supply device from a device associated with the user in the remote location.

Abstract: A red, green, and blue values for a fluid are received. A standard red, green, and blue values for the fluid are determined. A tolerance red, green, and blue values are determined for the fluid based on the standard red, green, and blue value for the fluid. An updated red, green, and blue values for the fluid are received. Whether any of the updated red, green, and blue values for the fluid are outside of the associated tolerance red, green, and blue values for the fluid is determined.

Abstract: An integrated vascular delivery system having a frame configured to receive a catheter insertable in a patient to deliver fluid at an insertion site. The frame includes a first hub, a second hub, and a pair of flexible lateral members extending between the hubs and including a tubular lateral member. The system also includes a fluidic channel that fluidically communicates with the catheter, wherein the fluidic channel passes through the tubular lateral member and at least one of the hubs, and includes a fixed turnabout portion in which fluid flows in a direction different from that within the catheter. The first and second hubs provide anchoring points on the patient distributed around the insertion site and on opposite ends of the catheter, thereby anchoring the frame to the patient and stabilizing the catheter. A method is provided for using an integrated vascular delivery system.

Abstract: A medication injection pen, including a housing, a dose set knob (DSK) comprising an internal key, and a dose stop member engaging the dose set knob. Rotation of the dose set knob to set a medication dose causes rotation of the dose stop member with respect to the dose set knob, and when the dose set knob is rotated to a last dose setting position, the dose stop member rotationally abuts the internal key thereby preventing further rotational movement of the dose set knob in a dose setting direction.